Table 2—

Differences of mean of baseline characteristics, yearly decline in lung function and cholesterol levels in 37 lymphangioleiomyomatosis(LAM) patients receiving statins and 37 matched# LAM patient controls not receiving statins

StatinNo statinMean difference95% CIp-value
Age yrs52.2±1.151.6±1.20.5-1.1–2.10.498
Follow-up yrs2.5±0.33.0±0.30.2-0.4–0.80.523
Initial FEV1 % pred72.6±4.775.0±4.5-2.4-14.4–9.60.687
Initial DL,CO % pred68.1±4.072.7±3.5-4.6-15.4–6.20.392
Yearly change in FEV1 % pred-1.2±0.80.7±1.0-1.9-4.4–0.60.128
Yearly change in DL,CO % pred-3.6±1.00.13±1.1-3.7-6.6– -0.70.016
Minimum cholesterol levels+ mg·dL−1
 LDL96.1±4.4113.3±5.3-17.1-33.2– -1.00.038
  • Data are presented as mean±se, unless otherwise stated. CI: confidence interval; FEV1: forced expiratory volume in 1 s; % pred: % predicted; DL,CO: diffusing capacity of the lung for carbon monoxide; HDL: high-density lipoprotein; LDL: low-density lipoprotein. #: matched for age, years of follow-up, initial DL,CO % and FEV1; : based on the paired t-test, some comparisons of lipids are based on fewer pairs (n = 32 or 33) due to missing values; +: lowest measured cholesterol over the follow-up period.